Novan Company Profile (NASDAQ:NOVN)

About Novan (NASDAQ:NOVN)

Novan logoNovan, Inc. is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs). The Company's formulation science enables it to further tune the release of nitric oxide when applied to the skin by using the combinations of inactive ingredients. It is developing SB204 for the treatment of acne vulgaris in Phase III. The Company is developing its product candidate, SB206, for the treatment of external genital and perianal warts in Phase II. It is developing SB208, an investigational topical anti-fungal for the treatment of fungal infections of the skin and nails. It is developing SB204 for the treatment of inflammatory skin diseases. Its pipeline also includes SB414, a topical cream product candidate.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $78.57 million
  • Outstanding Shares: 15,969,000
Average Prices:
  • 50 Day Moving Avg: $5.27
  • 200 Day Moving Avg: $13.05
  • 52 Week Range: $3.52 - $30.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.57
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $100,000.00
  • Price / Sales: 785.67
  • Book Value: $1.30 per share
  • Price / Book: 3.78
Profitability:
  • EBIDTA: ($58,360,000.00)
Debt:
  • Current Ratio: 2.92%
  • Quick Ratio: 2.92%
Misc:
  • Average Volume: 259,010 shs.
  • Short Ratio: 1.44
 

Frequently Asked Questions for Novan (NASDAQ:NOVN)

What is Novan's stock symbol?

Novan trades on the NASDAQ under the ticker symbol "NOVN."

How were Novan's earnings last quarter?

Novan Inc (NASDAQ:NOVN) announced its quarterly earnings data on Friday, May, 12th. The company reported ($0.73) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.24. The company earned $0.10 million during the quarter, compared to analyst estimates of $10.80 million. View Novan's Earnings History.

Where is Novan's stock going? Where will Novan's stock price be in 2017?

4 brokers have issued 1 year target prices for Novan's stock. Their predictions range from $8.00 to $31.00. On average, they anticipate Novan's share price to reach $17.24 in the next twelve months. View Analyst Ratings for Novan.

Are investors shorting Novan?

Novan saw a increase in short interest in April. As of April 28th, there was short interest totalling 1,157,866 shares, an increase of 31.3% from the April 13th total of 881,898 shares. Based on an average trading volume of 165,909 shares, the days-to-cover ratio is presently 7.0 days. Approximately 12.8% of the company's stock are short sold.

Who are some of Novan's key competitors?

When did Novan IPO?

(NOVN) raised $46 million in an IPO on Wednesday, September 21st 2016. The company issued 3,800,000 shares at a price of $11.00-$13.00 per share. Piper Jaffray served as the underwriter for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who owns Novan stock?

Novan's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Driehaus Capital Management LLC (1.75%), Vanguard Group Inc. (1.14%), Geode Capital Management LLC (0.38%) and Prospera Financial Services Inc (0.17%). View Institutional Ownership Trends for Novan.

Who bought Novan stock? Who is buying Novan stock?

Novan's stock was acquired by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Vanguard Group Inc., Prospera Financial Services Inc and Geode Capital Management LLC. View Insider Buying and Selling for Novan.

How do I buy Novan stock?

Shares of Novan can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novan stock cost?

One share of Novan stock can currently be purchased for approximately $4.92.

Analyst Ratings

Consensus Ratings for Novan (NASDAQ:NOVN) (?)
Ratings Breakdown: 1 Hold Rating, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $17.24 (250.46% upside)

Analysts' Ratings History for Novan (NASDAQ:NOVN)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Piper Jaffray CompaniesSet Price TargetBuy$11.00LowView Rating Details
4/12/2017WedbushReiterated RatingNeutral$8.00HighView Rating Details
10/17/2016Credit Suisse Group AGInitiated CoverageOutperform$27.00 -> $18.97N/AView Rating Details
10/17/2016JMP SecuritiesInitiated CoverageOutperform$31.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for Novan (NASDAQ:NOVN)
Earnings by Quarter for Novan (NASDAQ:NOVN)
Earnings History by Quarter for Novan (NASDAQ:NOVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/12/2017Q1 2017($0.49)($0.73)$10.80 million$0.10 millionViewN/AView Earnings Details
3/20/2017Q4 16($1.14)($0.82)ViewN/AView Earnings Details
11/14/2016Q3 16($1.40)($5.76)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Novan (NASDAQ:NOVN)
2017 EPS Consensus Estimate: ($1.28)
2018 EPS Consensus Estimate: ($1.26)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.19)($0.19)($0.19)
Q2 20171($0.57)($0.57)($0.57)
Q3 20171($0.27)($0.27)($0.27)
Q4 20171($0.25)($0.25)($0.25)
Q1 20181($0.21)($0.21)($0.21)
Q2 20181($0.27)($0.27)($0.27)
Q3 20181($0.35)($0.35)($0.35)
Q4 20181($0.43)($0.43)($0.43)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Novan (NASDAQ:NOVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Novan (NASDAQ:NOVN)
Institutional Ownership Percentage: 12.75%
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Institutional Ownership by Quarter for Novan (NASDAQ:NOVN)
Insider Trades by Quarter for Novan (NASDAQ:NOVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2016Life Sciences Holdings L MalinMajor ShareholderBuy800,000$11.00$8,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Novan (NASDAQ:NOVN)
Latest Headlines for Novan (NASDAQ:NOVN)
Source:
DateHeadline
americanbankingnews.com logoNovan Inc Expected to Post Q2 2017 Earnings of ($0.57) Per Share (NOVN)
www.americanbankingnews.com - May 17 at 7:46 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Novan Inc (NOVN) to Announce -$0.58 Earnings Per Share
www.americanbankingnews.com - May 16 at 2:18 PM
americanbankingnews.com logoNovan Inc (NOVN) Posts Earnings Results, Misses Estimates By $0.24 EPS
www.americanbankingnews.com - May 15 at 11:18 AM
americanbankingnews.com logoNovan Inc (NOVN) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 13 at 7:20 AM
americanbankingnews.com logoZacks: Analysts Set $9.50 Target Price for Novan Inc (NOVN)
www.americanbankingnews.com - May 6 at 12:34 AM
finance.yahoo.com logoNovartis exercises exclusive option agreement with Conatus for the treatment of NASH
finance.yahoo.com - May 4 at 11:19 AM
finance.yahoo.com logoNovan Presents Preclinical Data from Inflammatory Skin Diseases Program
finance.yahoo.com - April 27 at 10:05 AM
finance.yahoo.com logoNovan Presents Safety Data for SB204 Program
finance.yahoo.com - April 27 at 10:05 AM
finance.yahoo.com logoAlcon announces EU launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device, to lower intraocular pressure (IOP) in patients with primary open-angle glaucoma
finance.yahoo.com - April 26 at 6:24 PM
americanbankingnews.com logo Novan Inc (NOVN) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - April 20 at 8:28 PM
finance.yahoo.com logoNovartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
finance.yahoo.com - April 18 at 10:06 AM
americanbankingnews.com logoNovan Inc (NOVN) Given a $11.00 Price Target by Piper Jaffray Companies Analysts
www.americanbankingnews.com - April 18 at 7:47 AM
streetinsider.com logoPre-Open Stock Movers 04/12: (NOVN) (NBIX) (BBRY) Higher; (NS) (ONVO) (TSCO) Lower (more...)
www.streetinsider.com - April 13 at 8:14 AM
americanbankingnews.com logoNovan Inc (NOVN) Receives "Neutral" Rating from Wedbush
www.americanbankingnews.com - April 12 at 2:01 PM
feeds.benzinga.com logo11 Biggest Mid-Day Gainers For Wednesday
feeds.benzinga.com - April 12 at 1:36 PM
msn.com logo19 Stocks Moving In Wednesday's Pre-Market Session
www.msn.com - April 12 at 10:25 AM
rttnews.com logoNovan Inc. (NOVN) Is Up Sharply On Phase 2 Study Results
www.rttnews.com - April 12 at 10:25 AM
finance.yahoo.com logoNovan Reports Positive Topline Results with SB208 in Phase 2 Trial
finance.yahoo.com - April 12 at 10:25 AM
finance.yahoo.com logoNovan's stock rockets after positive trial results
finance.yahoo.com - April 12 at 10:25 AM
benzinga.com logoExclusive: Novan CEO Talks Strategic Partnerships, 2017 Pipeline, Finance Evaluation
www.benzinga.com - March 27 at 6:21 PM
americanbankingnews.com logoAnalysts Issue Forecasts for Novan Inc's Q1 2017 Earnings (NOVN)
www.americanbankingnews.com - March 23 at 10:16 AM
streetinsider.com logoNovan (NOVN) Reports Departure of CFO Richard Peterson
www.streetinsider.com - March 22 at 6:54 PM
us.rd.yahoo.com logoNovan Reshapes Executive Management Team
us.rd.yahoo.com - March 22 at 6:54 PM
americanbankingnews.com logoNovan Inc (NOVN) Announces Quarterly Earnings Results
www.americanbankingnews.com - March 21 at 8:31 AM
bizjournals.com logoNovan’s loss grew in 2016, but optimistic on development
www.bizjournals.com - March 20 at 4:59 PM
americanbankingnews.com logoWedbush Reiterates Neutral Rating for Novan Inc (NOVN)
www.americanbankingnews.com - March 20 at 4:24 PM
us.rd.yahoo.com logoNovan Reports Fourth Quarter and Full Year 2016 Financial Results
us.rd.yahoo.com - March 20 at 9:57 AM
biz.yahoo.com logoNOVAN, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 20 at 9:57 AM
finance.yahoo.com logoSandoz announces winners of inaugural Healthcare Access Challenge (Sandoz HACk)
finance.yahoo.com - March 13 at 10:05 AM
us.rd.yahoo.com logoNovan Provides Update on SB204 Development Program
us.rd.yahoo.com - March 6 at 6:21 PM
bizjournals.com logoNovan stocks trading up after plummeting earlier this year
us.rd.yahoo.com - March 6 at 6:21 PM
fool.com logoHere's Why Novan Inc. Is Rising Today
www.fool.com - March 6 at 1:05 PM
us.rd.yahoo.com logoNovan Announces SB204 Program Update Conference Call and Webcast
us.rd.yahoo.com - March 3 at 11:53 PM
streetinsider.com logoNovan (NOVN) SB206 Phase 2 Results to be Presented at AAD - StreetInsider.com
www.streetinsider.com - March 3 at 6:51 PM
globenewswire.com logoNovan Announces SB204 Program Update Conference Call and Webcast - GlobeNewswire (press release)
globenewswire.com - March 3 at 6:51 PM
finance.yahoo.com logoNovan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
finance.yahoo.com - March 1 at 10:37 AM
rttnews.com logoRGLS Disappointed, NOVN Loses Face Over Acne Trial Data, AMGN Abuzz
www.rttnews.com - January 29 at 7:23 PM
us.rd.yahoo.com logoNovan Reports Topline Results from SB204 Phase 3 Pivotal Trials
us.rd.yahoo.com - January 29 at 12:00 AM
streetinsider.com logoNovan (NOVN) Names Anne Whitaker as CEO
www.streetinsider.com - January 26 at 11:25 PM
finance.yahoo.com logoAlcon launches new trifocal toric intraocular lens for patients with astigmatism undergoing cataract surgery
finance.yahoo.com - January 26 at 2:14 AM
finance.yahoo.com logoNovartis highlights progress towards access and environmental goals in 2016 Corporate Responsibility Performance Report
finance.yahoo.com - January 26 at 2:14 AM
streetinsider.com logoNovan (NOVN) Enters Licenses Agrement for SB204 with Sato Pharmaceutical in Japan
www.streetinsider.com - January 19 at 12:29 AM
finance.yahoo.com logoNovan Licenses SB204 to Sato for Acne in Japan
finance.yahoo.com - January 17 at 11:28 AM
biz.yahoo.com logoNOVAN, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - January 17 at 11:28 AM
finance.yahoo.com logo9:14 am Novan enters into an exclusive license agreement with Sato Pharmaceutical; will receive approx. $11 mln for the exclusive rights to develop and commercialize in Japan its SB204 for the treatment of acne vulgaris
finance.yahoo.com - January 17 at 11:28 AM
finance.yahoo.com logoNovartis invests in next generation therapies to reduce cardiovascular risk in patients with underlying lipid disorders
finance.yahoo.com - January 6 at 2:33 AM
finance.yahoo.com logoNovartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases
finance.yahoo.com - December 20 at 12:49 PM
finance.yahoo.com logoNovartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.
finance.yahoo.com - December 20 at 12:49 PM
finance.yahoo.com logoNovartis launches SMS for Life 2.0 in Nigeria to help improve access to essential medicines
finance.yahoo.com - December 12 at 10:03 AM
finance.yahoo.com logoNovan CEO Talks About The Company's Future: 'Our Focus Is Put On SB204'
finance.yahoo.com - December 9 at 11:52 PM

Social

Chart

Novan (NOVN) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff